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Monotherapy with interferon or nucleoside analog is generally not recommended during the immune-tolerant (IT) 
phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with 
hepatocellular carcinoma has increased interest in treating HBV in the IT phase. Small pediatric studies reported 
efficacy with combination nucleoside analog and interferon therapy. The aim of this study was to evaluate the safety 
and efficacy of the combination of entecavir and peginterferon in adults in the IT phase of chronic HBV infection. 
Hepatitis B e antigen (HBeAg)–positive adults with HBV DNA > 107 IU/mL and alanine aminotransferase (ALT) 
≤ 1.5 times the upper limit of normal (ULN) (male: ≤ 45, female: ≤ 30 U/L) received entecavir 0.5 mg daily for 8 
weeks followed by the addition of peginterferon alfa-2a 180 µg/week to entecavir for an additional 40 weeks. The 
primary endpoint was HBeAg loss and HBV DNA ≤ 1,000 IU/mL 48 weeks after end of treatment (EOT). Among 
28 participants from 11 sites, the median age was 37.2 (range: 22-61) years, 54% were male, and 96% were Asian. 
Nearly all were infected with genotype C (64%) or B (32%). Median baseline HBV DNA was 8.2 log10 IU/mL, and 
ALT was 0.9 times the ULN. Although one (4%) participant cleared HBeAg, none met the primary endpoint of 
both HBeAg loss AND HBV DNA ≤ 1,000 IU/mL 48 weeks post-EOT. ALT elevations > 5 times the ULN oc-
curred in eight (29%) participants, and none were associated with icterus. Forty-eight weeks posttreatment, HBV 
DNA rebounded to baseline levels in all participants, including the participant who lost HBeAg, and ALT values 
returned to near baseline levels in all but four participants. Conclusion: A lead-in strategy of 8 weeks of entecavir 
followed by combination peginterferon and entecavir therapy for 40 weeks had limited efficacy in adults in the IT 
phase of chronic HBV infection and cannot be recommended. (Hepatology 2019;69:2338-2348).
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Hepatitis B virus (HBV) infection remains a significant global public health problem, with roughly 250 million persons chronically 
infected worldwide.(1) Chronic HBV infection may 
result in progressive liver disease that leads to cir-
rhosis, end-stage liver disease, and hepatocellular 
carcinoma (HCC). The majority of individuals with 
chronic HBV acquire infection at birth or in early 
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childhood. The course of chronic infection has been 
divided into clinical phases based on virological 
characteristics, liver enzyme levels, and hepatic his-
tology.(2) The immune-tolerant (IT) phase is char-
acterized by the presence of hepatitis B e antigen 
(HBeAg), very high HBV DNA levels (> 107 IU/mL) 
but normal or near-normal aminotransferases, and 
minimal or no inflammation on liver biopsy, sug-
gesting that despite active viral replication, there is 
no immune response to the virus.(3) Most individu-
als in the IT phase are children or young adults who 
acquired infection by vertical transmission. The age 
of transition to the immune-active (IA) phase is vari-
able depending on HBV genotype and possibly race 
but typically occurs in adolescence or early adult-
hood.(3) Entry into the IA phase is characterized by 
a rise in alanine aminotransferase (ALT) levels and 
active inflammation on biopsy with fluctuating levels 
of HBV DNA. Repeated ALT flares and progres-
sive liver injury may occur with eventual clearance of 
HBeAg, often with the development of antibody to 
HBeAg (anti-HBe). After HBeAg clearance, patients 
may enter the immune control or inactive carrier (IC) 
phase of infection with low or undetectable levels of 
HBV DNA and normal ALT values, or they may 
progress to HBeAg-negative IA disease with ongo-
ing active hepatitis and fluctuating HBV DNA levels 
despite clearance of HBeAg.(3)
National and international clinical practice guide-
lines recommend treatment for HBV infection during 
the IA phases (HBeAg positive or HBeAg nega-
tive) of infection and for patients with cirrhosis.(4,5) 
Treatment during the IT phase has not been recom-
mended because of the presence of minimal liver dis-
ease and limited efficacy of interferon or nucleoside 
analog monotherapy.(4,5) With recognition that high 
HBV DNA levels and persistence of HBeAg are asso-
ciated with an increased risk of HCC, and that during 
the IT phase, HBV-specific T cells are present and 
able to proliferate and produce cytokines,(6) there has 
been increased interest in treating HBV during the 
IT phase. A pilot study of 23 children in the IT phase 
treated with lamivudine for 8 weeks followed by the 
addition of interferon for 44 weeks showed HBeAg 
of Health (NIH) (Marc G. Ghany, M.D.). Additional funding to support this study was provided to Kyong-Mi Chang, M.D., the Immunology 
Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases grant P30DK50306, NIH Public Health Service research 
grant M01-RR00040); Richard K. Sterling, M.D., M.Sc. (UL1 TR000058, National Center for Advancing Translational Sciences [NCATS], 
NIH); Norah A. Terrault, M.D., M.P.H. (Clinical and Translational Science Awards [CTSA] grant number UL1 TR000004); Michael W. 
Fried, M.D. (CTSA grant number UL1T R001111); and Anna Suk-Fong Lok (CTSA grant number UL1 RR024986 and U54 TR001959). 
Additional support was provided by Bristol-Myers Squibb and Genentech through clinical trial agreements with the NIDDK and Roche Molecular 
Systems through a Cooperative Research and Development Agreement with the NIDDK.
© 2018 by the American Association for the Study of Liver Diseases.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.30417
Potential conflict of interest: Dr. Tsai consults for and advises for Bristol-Myers Squibb. He also consults for, advises, is on the speakers’ bureau of, 
and received grants from Gilead. Dr. Chung received grants from Gilead, AbbVie, Bristol-Myers Squibb, Merck, Janssen, Roche, and Boehringer 
Ingelheim. Dr. Feld consults for and received grants from AbbVie, Gilead, Janssen, and Merck. He also consults for MedImmune and ContraVir. 
Dr. Khalili received grants from Gilead, AbbVie, and Intercept. Drs. Lok and Terrault received grants from Bristol-Myers Squibb and Gilead.
aRtICle INFoRMatIoN:
From the 1 Toronto Centre for Liver Disease,  University of Toronto, Toronto, Canada; 2 University of California San Francisco, San 
Francisco, CA; 3 Graduate School of Public Health,  University of Pittsburgh, Pittsburgh, PA; 4 Massachusetts General Hospital, 
Harvard University, Boston, MA; 5 University of Hawaii, Honolulu, HI; 6 Baylor University Medical Center, Baylor University, 
Dallas, TX; 7 San Francisco Center for Liver Disease,  California Pacific Medical Center, San Francisco, CA; 8 Liver Diseases 
Branch, National Institutes of Diabetes and Digestive and Kidney Diseases,  National Institutes of Health, Bethesda, MD; 
9 University of Michigan, Ann Arbor, MI; 10 The Hepatitis B Research Network.
addReSS CoRReSpoNdeNCe aNd RepRINt ReQUeStS to: 
Jordan J. Feld, M.D., M.P.H.
Toronto Centre for Liver Disease
Toronto General Hospital, University Health Network
200 Elizabeth Street 9EB-240
Toronto, ON M5G 2C4 Canada
E-mail: Jordan.feld@uhn.ca
Tel.: +1 416 340 4584
Feld et al. Hepatology, June 2019
2340
seroconversion in five (22%) and hepatitis B surface 
antigen (HBsAg) loss in four (17%) children.(7) Based 
on these promising results, the Hepatitis B Research 
Network (HBRN) developed a clinical trial to assess 
combination therapy using entecavir, a more potent 
antiviral agent than lamivudine, followed by the addi-
tion of peginterferon in adult patients in the IT phase 
of chronic HBV infection.
Patients and Methods
HBRN
The HBRN is an National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK)–
funded, multicenter, prospective study of chronic 
hepatitis B in both children and adults followed at 
28 clinical sites in the United States and Canada, the 
goals of which are to better define the natural his-
tory, pathogenesis, and therapy of chronic HBV. The 
HBRN includes both a pediatric and an adult cohort 
study and has initiated three therapy trials: two trials 
of entecavir and peginterferon (one in children and 
one in adults) with IT chronic HBV and one trial of 
tenofovir and peginterferon in adults with IA chronic 
HBV. This report is a description of the design and 
results of the open-label, adult IT study carried out 
at 11 adult clinical sites in the United States and at 
one clinical site in Canada. The Data Coordinating 
Center for the HBRN was located at the University 
of Pittsburgh, Pittsburgh, PA.
paRtICIpaNtS
Participants who met the following criteria were 
eligible for enrollment: at least 18 years old, HBsAg 
positive, HBeAg positive, HBV DNA > 107 IU/mL 
on two occasions greater than 12 weeks apart and 
within 6 weeks of enrollment, and three documented 
ALT values less than 1.5 times the upper limit of nor-
mal (ULN) over the year before study entry. The ULN 
differed for men (30 U/L) and women (20 U/L). 
Initially men with ALT ≤ 60 U/L and women with 
ALT ≤ 40 U/L were eligible; however, the study was 
amended to ensure all participants were truly in the 
IT phase to include only men with ALT ≤ 45 U/L 
and women with ALT ≤ 30 U/L. Participants more 
than 50 years old were required to have had a liver 
biopsy within 96 weeks of enrollment documenting 
a histologic activity index (HAI) score < 3 and fibro-
sis stage ≤ 1. Key exclusion criteria included a past 
or current history of hepatic decompensation (asci-
tes, variceal bleeding, hepatic encephalopathy), HCC, 
solid organ or bone marrow transplantation, platelet 
count < 120,000/mm3, direct bilirubin > 0.5 mg/dL, 
albumin < 3.5 g/L, International Normalized Ratio 
> 1.5, creatinine clearance < 50 mL/minute, human 
immunodeficiency virus (HIV), hepatitis D or hep-
atitis C virus coinfection, preexisting psychiatric or 
autoimmune disease, or any other medical condition 
potentially exacerbated by interferon therapy. A full 
list of inclusion and exclusion criteria is provided in 
Supporting Tables S1 and S2.
Originally designed as a randomized trial with 
a control arm, the protocol was revised to be a sin-
gle-arm pilot treatment study because of low enroll-
ment. Participants previously randomly assigned to 
the control group were offered the option of enrolling 
in the revised protocol, provided that they still met 
trial eligibility criteria. The protocol was approved by 
the HBRN Steering Committee and the institutional 
review boards (research ethics board in the case of the 
Toronto site) of the participating sites, and all partic-
ipants provided written informed consent. The study 
was overseen by an independent data safety monitor-
ing board appointed by the NIDDK to monitor the 
clinical studies of the HBRN. The ClinicalTrials.gov 
identifier was NCT01369199.
After amendment to a single-arm pilot treatment 
study, the sample size was reestimated based on 
desired precision of the point estimate of the primary 
outcome (i.e., assuming 25% would meet the primary 
endpoint and a 95% Clopper-Pearson confidence 
limit within ± 15% of the estimated percentage, the 
revised sample size was 40 participants).
tReatMeNt
In the initial protocol, participants were randomly 
assigned to treatment or observation. After the proto-
col was revised, those in the control arm were offered 
the option to move to the treatment arm, and subse-
quent enrollees received open-label therapy. Treatment 
consisted of open-label entecavir 0.5 mg/day for 
8 weeks followed by entecavir combined with peginter-
feron alfa-2a 180 µg/week for an additional 40 weeks. 
After starting therapy, study visits occurred at weeks 
Hepatology, Vol. 69, No. 6, 2019 Feld et al.
2341
8, 12, 16, 20, 24, 30, 36, 42, and 48, at which point all 
treatment was stopped and participants were followed 
for an additional 48 weeks with visits at weeks 52, 60, 
72, and 96 (Fig. 1). Entecavir was provided by Bristol-
Myers Squibb (New York, NY), and peginterferon 
alfa-2a was provided by Genentech (San Francisco, 
CA) under separate clinical trial agreements with the 
NIDDK.
eNdpoINtS
The primary efficacy endpoint was the loss of 
HBeAg and HBV DNA ≤ 1,000 IU/mL at the end of 
follow-up (EOF; 48 weeks following the end of treat-
ment [EOT]). The primary safety endpoint was the 
frequency of adverse events (AEs) and serious AEs 
(SAEs). Secondary efficacy endpoints were assessed 
at the EOT (i.e., week 48 for those who completed 
treatment per protocol) and at the EOF (i.e. week 96 
for those who completed the full 48 weeks of treat-
ment). Secondary endpoints included loss of HBsAg, 
HBsAg seroconversion, loss of HBeAg, HBeAg sero-
conversion, ALT < 1.5 times the ULN, ALT normal-
ization (male: < 30 U/L, female: < 20 U/L), HBV 
DNA ≤ 1,000 IU/mL, and HBV DNA < 20 IU/mL. 
Other post hoc endpoints included change in ALT and 
quantitative HBsAg from baseline. ALT elevations 
≥ 2-fold the baseline were categorized by the height 
of elevation compared with the ULN using standard 
hepatotoxicity grading: grade 1 as > 1-3 times the 
ULN, grade 2 as > 3-5 times the ULN and grade 3 as 
> 5 times the ULN. Icteric ALT elevations are those 
associated with a bilirubin concentration > 2.5 mg/dL. 
Participants’ maximum decline in quantitative 
HBsAg and HBeAg during therapy were calculated 
and categorized as ≤ 0.5 versus > 0.5 log10 IU/mL and 
≤ 1.0 versus > 1.0 log10 IU/mL.
VIRologICal aSSayS
Study eligibility was based on qualitative HBeAg 
and HBsAg results performed at the individual 
sites. Efficacy endpoints were based on quantita-
tive HBeAg and HBsAg (Elecsys; Roche Molecular 
Systems, Branchburg, NJ) assays performed at the 
HBRN central virology laboratory at the University of 
Washington, with lower limits of detection (LLODs) 
of 0.3 IU/mL for HBeAg and 0.05 IU/mL for 
HBsAg. HBV DNA testing was performed centrally 
using a real-time PCR assay (COBAS Ampliprep/
COBAS TaqMan Test, version 2.0; Roche Molecular 
Systems) with a lower limit of quantification of 
20 IU/mL and an LLOD of 10 IU/mL. HBV geno-
typing was performed at the Molecular Epidemiology 
and Bioinformatics Laboratory in the Division of 
Viral Hepatitis at the Centers for Disease Control 
and Prevention using mass spectrometry.(8)
StatIStICal aNalySIS
Descriptive statistics (median, range) and boot-
strapped 95% confidence intervals (CIs) about medi-
ans are reported for continuous variables. Frequencies 
and percentages are reported for categorical variables. 
The primary efficacy analysis was performed includ-
ing all enrolled participants. Participants who did not 
have primary endpoint data were considered as treat-
ment failures. The percentage of participants achiev-
ing the efficacy endpoints was summarized with the 
point estimate and the 95% exact binomial CI. For 
FIg. 1. Trial design. Entecavir 0.5 mg daily alone for 8 weeks followed by peginterferon alfa-2a 180 µg/week combined with entecavir 
for an additional 40 weeks. Endpoints were evaluated at the EOT (week 48) and 48 weeks after treatment completion (week 96). Weeks 
52, 60, 72, and 96 correspond to 4, 12, 24, and 48 weeks after EOT, respectively, for those who discontinued treatment early.
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safety endpoints, rates per person-year and 95% CIs 
about a Poisson variable are shown. For post hoc cal-
culations of aggregate treatment response for HBV 
DNA, HBsAg, HBeAg, and ALT, participants who 
stopped therapy before the given time point or who 
did not have laboratory results were excluded (i.e., 
per-protocol analysis). One participant who was never 
treated with study medications was excluded for post 
hoc analyses. SAS 9.3 (SAS Institute, Cary, NC) and 
R 3.3.1 were used for statistical analysis and graphical 
display.
Results
paRtICIpaNt CHaRaCteRIStICS
Of 58 patients screened, 29 met eligibility criteria 
and were enrolled in the trial. Three of these partici-
pants were randomly assigned to the control arm and 
two agreed to move to the treatment arm after the 
protocol amendment (both still met eligibility crite-
ria), whereas the other participant refused consent, 
leaving 28 participants in the treatment arm. Reasons 
for exclusion included refused consent (n = 16); labo-
ratory exclusion for HBV DNA; ALT level; platelet, 
hemoglobin, or neutrophil count (n = 13); and other 
medical condition (n = 1) (Supporting Fig. S1). Of the 
28 who were to start treatment, 15 (54%) were male, 
27 (96%) were Asian, the median age was 37.2 years 
(range: 22-61 years), and median body mass index was 
22.4 (range: 18.0-28.3) kg/m2. There were 18 (64%) 
individuals with genotype C, nine (32%) with geno-
type B, and one (4%) with genotype E infection. At 
baseline, the median HBV DNA level was 8.2 (range: 
7.2-8.8) log10 IU/mL, and the median quantitative 
HBsAg level was 4.7 (range: 4.2-5.1) log10 IU/mL. 
Baseline ALT values ranged from 9 to 47 U/L or 0.5 
to 1.6 times the ULN (median = 0.9 times the ULN), 
and 19 (68%) had values at or below the ULN. The 
median FIB-4 score was 0.7 (range: 0.4-2.3). One 
participant who was 61 years of age underwent liver 
biopsy and had an HAI = 1 and Ishak fibrosis = 0. 
Other baseline laboratory parameters are shown in 
Table 1.
tReatMeNt oUtCoMeS
One participant withdrew consent before the first 
dose of medication and was counted as failing to 
meet study efficacy endpoints; however, on-treatment 
results for this participant were excluded from calcu-
lations of summary statistics. Two additional partici-
pants were not available for the last follow-up visit, 
leaving 25 participants who completed 48-week post-
treatment follow-up (Supporting Fig. S1). Among 
28 participants, 27 adults initiated treatment and 20 
(71%) completed the full 48 weeks of entecavir and 
40 weeks of peginterferon treatment without dose 
reduction or early discontinuation. Four participants 
taBle 1. Baseline Characteristics
Characteristics
Total N = 28  
n (%) or Median (Range)
Demographics
Sex
Male 15 (54)
Female 13 (46)
Race
Black/African American 1 (4)
Asian 27 (96)
Age (years) 37.2 (22.2-61.2)
BMI (kg/m2) 22.4 (18.0-28.3)
Virology and serology
HBV genotype
B 9 (32)
C 18 (64)
E 1 (4)
HBeAg (+) 28 (100)
HBV DNA (log10 IU/mL) - screening 8.3 (7.4-8.8)
HBV DNA (log10 IU/mL) - baseline 8.2 (7.2-8.8)
Quantitative HBeAg (log10 IU/mL) 3.3 (2.3-3.6)
Quantitative HBsAg (log10 IU/mL) 4.7 (4.2-5.1)
ALT (U/L): screening 21 (9-47*)
Males 32 (16-47*)
Females 18 (9-26)
ALT (U/L): baseline 21 (9-47)
Males 27 (14-47)
Females 15 (9-30)
AST (U/L) 20 (15-30)
FIB-4 0.7 (0.4-2.3)
INR 1.0 (0.9-1.1)
Total bilirubin (mg/dL) 0.6 (0.3-2.0)
Albumin (g/dL) 4.2 (3.5-4.8)
Platelets (x 103/mm3) 242.5 (137-325)
White blood cells (x 103/mm3) 5.0 (3.0-9.1)
*A male participant with ALT = 47 U/L was eligible for enroll-
ment under the study protocol version 6.0 (ALT ≤ 60 U/L for 
males, ≤ 40 U/L for females). The study protocol version 7.0 was 
revised as ALT ≤ 45 U/L for males and ≤ 30 U/L for females.
Abbreviation: AST, aspartate aminotransferase.
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had at least one peginterferon dose reduction or inter-
ruption. Three participants discontinued one or both 
study medications. Two participants discontinued 
peginterferon early because of an AE, one at week 36 
due to altered thyroid function and the other at week 
35 due to a diagnosis of Graves disease. The average 
weekly dose was 177 µg (range: 90-180 µg) for the 
24 participants who did not discontinue peginterferon 
early, representing 98% of the total expected dose.
pRIMaRy eFFICaCy eNdpoINt
No participant met the primary endpoint of both 
HBeAg loss and HBV DNA ≤ 1,000 IU/mL 48 weeks 
after treatment ended (week 96 for those who com-
pleted treatment) (Table 2, Fig. 2). One participant lost 
HBeAg at week 48 and remained HBeAg-negative, 
anti-HBe positive, and HBsAg positive at week 96. 
However, HBV DNA levels, which were suppressed 
to being undetectable by the EOT, rebounded to high 
levels (7.5 log10 IU/mL) by week 96, accompanied by 
an increase in ALT levels from 27 U/L at the EOT 
to 70 U/L at week 96. Viral sequencing confirmed the 
presence of the double Basal Core Promotor muta-
tions (A1762T and G1764A) but the absence of the 
precore mutation (G1896A) at baseline and at last 
study follow-up. No posttrial follow-up was available 
for this individual.
One other participant had discrepant qualita-
tive and quantitative HBeAg results throughout the 
study. At screening, the local qualitative HBeAg was 
positive, but the central quantitative HBeAg at base-
line was below the limit of detection (< 0.3 IU/mL). 
Multiple results from both assays were unchanged, 
and this participant remained HBeAg positive by 
local qualitative testing but HBeAg negative by the 
central quantitative assay throughout the course of 
therapy and follow-up, with a similar HBV DNA 
curve during and after treatment as seen in other par-
ticipants. This individual with discrepant qualitative 
and quantitative HBeAg results was not regarded as 
having HBeAg loss, and quantitative HBeAg results 
were not included in aggregate summary statistics for 
HBeAg (Table 2, Fig. 3C).
HBV dNa ReSpoNSe
Median log10 HBV DNA levels declined during 
the 8 weeks of entecavir monotherapy from 8.2 (range: 
7.2-8.8) log10 IU/mL at baseline to 4.9 (range: 3.2-
6.0) log10 IU/mL at week 8. At the EOT, HBV DNA 
levels were ≤ 1,000 IU/mL in all 26 participants who 
completed therapy and < 20 IU/mL in five partici-
pants (Table 2). Only one of these five participants 
had undetectable HBV DNA (< 10 IU/mL). No par-
ticipants experienced on-treatment virological break-
through. After stopping therapy, median HBV DNA 
levels rebounded to 8.3 (range: 6.9-9.0) log10 IU/mL 
by week 96 (Fig. 2A), and levels were within 0.3 log10 
IU/mL of baseline values in all but four participants 
taBle 2. efficacy endpoints
EOT EOF
n = 28 (%) 95% CIs (%) n = 28 (%) 95% CIs (%)
Endpoints
HBsAg loss 0 (0) (0.0-12.3) 0 (0) (0.0-12.3)
HBsAg seroconversion 0 (0) (0.0-12.3) 0 (0) (0.0-12.3)
HBeAg loss* 1 (4) (0.1-18.3) 1 (4) (0.1-18.3)
HBeAg seroconversion 1 (4) (0.1-18.3) 1 (4) (0.1-18.3)
HBV DNA < 20 IU/mL 5 (18) (6.1-36.9) 0 (0) (0.0-12.3)
HBV DNA ≤ 1,000 IU/mL 26 (93) (76.5-99.1) 0 (0) (0.0-12.3)
ALT < 1 x ULN 11 (39) (21.5-59.4) 13 (46) (27.5-66.1)
ALT < 1.5 x ULN 16 (57) (24.5-62.8) 21 (75) (55.1-89.3)
Primary endpoint
HBeAg loss* and HBV DNA ≤ 1,000 IU/mL 1 (4) (0.1-18.3) 0 (0) (0.0-12.3)
*The individual with discrepant qualitative (positive) and quantitative (negative) HBeAg results over time was not regarded as having 
HBeAg loss.
Analyses were performed using all enrolled participants.
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(Fig. 2B). In the subject (identifier = 23) who became 
HBeAg negative, HBV DNA was 7.5 log10 IU/mL at 
week 96 compared with 8.2 log10 IU/mL at baseline 
(Fig. 2B).
HBeag ReSpoNSe
Median quantitative HBeAg levels declined from 
3.3 (range: 2.3-3.6) log10 IU/mL to 2.7 (range: 
LLOD-3.2) log10 IU/mL by week 48 and rebounded 
to 3.4 (range: LLOD-3.6) log10 IU/mL by week 
96 (Fig. 3A). As noted, one participant experienced 
HBeAg seroconversion at week 48 of treatment 
that persisted to the EOF, but HBV DNA levels 
rebounded to near baseline levels with accompanying 
increase in ALT (Fig. 3C).
HBsag ReSpoNSe
No participants cleared HBsAg during the study. 
Median quantitative HBsAg levels were similar at 
baseline (4.7 [range: 4.2-5.1] log10 IU/mL) and week 
8 (4.7 [range: 4.1-5.1] log10 IU/mL) during ente-
cavir monotherapy. After the addition of peginter-
feron, median HBsAg levels declined to 4.1 (range: 
1.7-4.9) log10 IU/mL by week 48 but rebounded 
to 4.9 (range: 4.0-5.3) log10 IU/mL by the EOF 
(Fig. 3B). During therapy, the maximum HBsAg 
decline was 3.1 log10 IU/mL. Of the 27 treated par-
ticipants, 19 (70%) had a more than 0.5 log10 decline 
and six (22%) had a more than 1.0 log10 decline in 
HBsAg levels.
alt ReSpoNSeS
None of the 27 participants who started therapy 
experienced an ALT elevation of 2-fold the base-
line during lead-in entecavir monotherapy, whereas 
19 (70%) had such an elevation during combination 
therapy, and these elevations were above 5 times the 
ULN in eight (30%). There were no icteric ALT ele-
vations (bilirubin > 2.5 mg/dL), and treatment was 
not altered because of ALT increases. All ALT ele-
vations resolved after completing treatment, and ALT 
levels returned to near baseline levels in most partic-
ipants. (Fig. 4). In addition, seven grade 1 and four 
grade 2 ALT elevations were noted during combina-
tion therapy.
At the EOT, ALT levels decreased, and by EOF, 
13 of 28 (46%) participants had normal ALT and 21 
of 28 (75%) participants had values < 1.5 times the 
ULN (Table 2). At week 96, ALT was above 1.5 times 
the ULN in four of 25 subjects, but in no instance 
was ALT more than twice the baseline level (Fig. 4B). 
Three of these four were women with ALT values 
ranging from 32 to 37 U/L, compared with baseline 
values ranging from 15 to 30 U/L. The other partic-
ipant was the person who had HBV DNA rebound 
despite HBeAg seroconversion and ALT of 70 U/L at 
week 96 compared with 37 U/L at baseline.
SaFety
There were 42 treatment-emergent AEs (i.e., 
from first treatment to last follow-up) reported by 14 
FIg. 2. HBV DNA levels. (A) Median and 95% CIs of HBV DNA levels are shown at baseline, during treatment, and after treatment. 
(B) HBV DNA levels at baseline are plotted against HBV DNA at the EOF (week 96), indicating that HBV DNA levels returned to 
near baseline levels (> 107 IU/mL) in all participants, including the individual who cleared HBeAg at the EOF.
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FIg. 3. (A) Quantitative HBeAg, (B) quantitative HBsAg, and (C) laboratory results over time in the participant who had HBeAg 
seroconversion. Quantitative (A) HBeAg and (B) HBsAg levels are shown before, during, and after treatment. (C) The pattern of ALT, 
HBV DNA, and quantitative HBsAg and HBeAg are shown in the individual who underwent HBeAg seroconversion on treatment. 
This patient stopped peginterferon at week 35 because of a diagnosis of Graves disease but continued entecavir until week 48. The 
decrease in HBeAg and HBsAg levels and sharp rise in ALT levels occurred after peginterferon was stopped and before entecavir was 
discontinued. The week 48 line indicates the end of entecavir treatment and the first time HBeAg was found to be negative.
FIg. 4. ALT levels. (A) Median and 95% CI of ALT levels are shown before, during, and after treatment. (B) ALT levels at baseline 
are plotted against ALT levels at EOF (week 96), indicating that ALT levels returned to near baseline levels in most participants. ALT 
values of 1.5 times the ULN are indicated for men (45 U/L) in dashed lines and women (30 U/L) in dotted lines, respectively.
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participants (Supporting Table S3A), none of which 
were scored as probably or definitely related to ente-
cavir; in contrast, 14 (33%) were considered proba-
bly or definitely related to peginterferon (Supporting 
Table S3B,S3C). The treatment-emergent AE rate 
was 86 per 100 person-years (95% CI: 64-117 per 100 
person-years). The treatment-emergent SAE rate was 
2 per 100 person-years (95% CI: 0-15 per 100 per-
son-years). Most AEs were mild (50%) or moderate 
(43%) in severity (Supporting Table S3B). The most 
common AEs were dermatologic (24%) and urologi-
cal (14%) (Table 3). Three AEs led to three separate 
treatment interruptions of peginterferon in one par-
ticipant. Two participants stopped peginterferon ther-
apy due to an AE possibly related to peginterferon, 
one at week 36 due to altered thyroid function and 
the other at week 35 due to a specific diagnosis of 
Graves disease. Both participants continued enteca-
vir. One SAE was reported during the off-treatment 
observation period, a case of malaria, considered to be 
unrelated to treatment.
Discussion
National and international guidelines do not rec-
ommend treatment during the IT phase of chronic 
HBV infection, largely because of the limited efficacy 
of currently available therapies.(4,5) This study evalu-
ated adding peginterferon to entecavir for 40 weeks 
after 8 weeks of lead-in entecavir monotherapy. Only 
one of 28 (3.6%) participants achieved HBeAg sero-
conversion, and this individual had rebound in HBV 
DNA and ALT posttreatment, transitioning to the 
HBeAg-negative IA phase rather than to the IC state. 
No patients achieved off-therapy virological control or 
HBsAg loss.
Although the combination treatment was not 
effective, this trial provides some useful insights. The 
concept of immune tolerance was first proposed based 
on the observation that, despite high levels of vire-
mia, patients in the IT phase have minimal or no 
hepatic inflammation, suggesting a lack of immune 
recognition or tolerance to the virus.(2) However, 
more in-depth characterization of the HBV-specific 
immune response in different phases of chronic HBV 
infection has challenged the concept of immune toler-
ance. Young patients in the IT phase have been shown 
to have similar or greater frequency and reactivity of 
HBV-specific T cells in the peripheral blood com-
pared with older patients in the IA phase of disease.(9) 
Furthermore, viral diversity in young IT patients 
suggests immune selection pressure, questioning the 
concept of true tolerance to the virus.(10) Bertoletti 
and colleagues have noted that the main difference 
between the IT phase and the IA phase is not immune 
tolerance but the presence of an inflammatory milieu 
in the IA phase that drives nonspecific inflammation 
in response to recognition of HBV by T cells and have 
thus suggested renaming the IT phase as the “nonin-
flammatory, high viremic” phase of disease.(6) This is 
reflected in the recent European Association for the 
Study of the Liver HBV clinical practice guidelines 
in which the authors proposed a nomenclature for the 
phases of chronic HBV infection and suggested that 
the IT phase be renamed “HBeAg-positive Chronic 
Infection” to distinguish it from the IA phase, which 
they proposed to rename “HBeAg-positive Chronic 
Hepatitis.”(4) The data from our study are notable for 
the fact that despite a rapid rebound in HBV DNA 
levels after stopping entecavir and peginterferon to 
near baseline values, there was no associated hepatitis 
flare, with ALT values settling out at or near base-
line levels. Continued follow-up showed that ALT 
values remained stable, indicating that the patients 
returned to the same “tolerant” or “noninflammatory” 
state posttreatment. This is similar to what was seen 
after stopping 4 years of nucleoside analog therapy 
in IT patients(11) and contrasts notably with studies 
of antiviral therapy withdrawal in HBeAg-positive 
patients who started therapy in the IA phase of dis-
ease, in whom there were reports of severe or even 
taBle 3. treatment-emergent aes by System (n = 42) 
Reported by 14 participants
System Number of AEs (%)
Dermatologic 10 (24)
Urological 6 (14)
Gastrointestinal 4 (10)
Constitutional symptom 4 (10)
Ear/nose/throat 4 (10)
Endocrine 3 (7)
Neurological 3 (7)
Infection 2 (5)
Musculoskeletal 2 (5)
Hematological 2 (5)
Ophthalmic 1 (2)
Severe respiratory 1 (2)
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fatal withdrawal hepatitis.(12) These data suggest that 
the immune response to HBV is indeed different in 
patients in the IT and IA phase of chronic HBV 
infection. Studies of nucleoside analog withdrawal 
in HBeAg-negative patients have also reported ALT 
flares in 53%-76% of patients in association with viral 
rebound.(13-15)
Despite the lack of hepatitis flares after stopping 
treatment, ALT elevations to more than twice baseline 
occurred in 19 patients during peginterferon therapy, 
and levels rose to above 5 times the ULN in eight 
(30%) participants. Declines in quantitative HBsAg 
and HBeAg levels of at least 0.5 log10 IU/mL were 
also seen during combination therapy and were more 
common in those with ALT elevations, possibly sug-
gesting that the ALT elevations were associated with 
viral control. Neither ALT flares nor declines in quan-
titative HBsAg or HBeAg levels occurred during the 
8 weeks of entecavir monotherapy. These results are 
in keeping with previous data showing that HBsAg 
decline rarely occurs during nucleoside analog ther-
apy but is commonly observed during peginterferon 
treatment.(16)
Previous studies of interferon therapy for adult IT 
patients showed negligible rates of HBeAg or HBsAg 
loss.(17) Trials of nucleoside therapy in the IT patients 
have shown that HBV DNA can be suppressed, but 
HBeAg and HBsAg loss are rare.(18) However, small 
trials in children of interferon treatment after a lead-in 
of 8 weeks of lamivudine reported HBeAg serocon-
version rates of up to 39% and rates of HBsAg loss 
of up to 21%.(7,19) Part of the rationale for combining 
a nucleoside analog with interferon is the observation 
that viral suppression may lead to some degree of res-
toration of HBV-specific immune responses, which 
may then promote a more robust immune response 
driven by interferon.(20-22) We hypothesized that by 
using a more potent agent such as entecavir, we might 
achieve similar results in adult patients to those seen 
in children. A parallel HBRN study in children found 
that 3% had durable HBeAg and HBsAg clearance 
with undetectable HBV DNA and normal ALT. 
Although there were responses in children but none 
in adults, the CIs around the response rates were sim-
ilar. Notably, in the one adult participant who cleared 
HBeAg and developed anti-HBe in our study, HBV 
DNA levels increased after stopping therapy, and 
ALT levels rose to 70 U/L at last follow-up. Although 
it is difficult to make strong inferences from one 
individual, it raises the possibility that therapy was 
actually harmful to this participant, leading to a loss of 
“tolerance” and the development of HBeAg-negative 
IA disease. Similarly, in a study of nucleoside analog 
monotherapy in 20 adult IT patients, HBeAg loss 
occurred in three patients after treatment cessation, 
and one developed HBeAg-negative active disease.(11)
This study has important limitations, most notably 
the lack of a control arm. The original protocol was 
designed to include an untreated control arm; how-
ever, recruitment was lower than anticipated, largely 
because of a low frequency of eligible IT patients 
in the HBRN sites, demonstrating the challenge of 
studying this population in North America. To gain 
some insight into the effect of therapy compared with 
the natural history of the IT phase, we evaluated the 
virological and clinical parameters of study partici-
pants before entering this trial while they were fol-
lowed as part of the prospective HBRN cohort study. 
Because of variable duration of follow-up, it is difficult 
to make formal comparisons, but there were few to 
no changes in HBV DNA and HBsAg levels among 
the participants before starting therapy. Second, the 
overall sample size was smaller than planned; how-
ever, the very limited response rate makes it unlikely 
that a significant therapeutic effect was missed. Based 
on the CIs, a maximum of a 12% response rate could 
have been missed. Third, the study consisted of almost 
exclusively Asian patients with genotypes B and C; 
however, the IT phase is most frequently observed 
in Asians who acquire HBV perinatally. Fourth, the 
median age of participants was 37.2 years and eight 
(29%) were above 40 years of age, older than is often 
seen in the IT phase. Age was not an apparent deter-
minant of response, but whether younger patients may 
have responded differently as suggested by the two 
responders in the HBRN trial in children is unknown. 
Fifth, it is possible that a longer duration of combi-
nation therapy may have led to greater responses, 
given that in many individuals, quantitative HBsAg 
levels were trending downward at the end of therapy; 
however, tolerability of peginterferon-based therapy 
for greater than a year is not likely to be a clinically 
attractive treatment strategy.
In conclusion, an 8-week lead-in of entecavir fol-
lowed by the addition of 40 weeks of peginterferon 
was ineffective in adults in the IT phase of chronic 
HBV infection. The lack of hepatitis flare on rebound 
viremia after stopping antiviral therapy suggests that 
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the immune response to HBV in the IT phase is 
truly distinct from that in the IA phase of disease. 
Understanding the mechanisms leading to toler-
ance or at least lack of inflammation may be key to 
developing therapeutic strategies for the IT phase of 
chronic HBV.
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